Stockreport

Rocket Pharmaceuticals Presents Updated Long-Term Phase 1/2 Clinical Data of RP-L102 in Fanconi Anemia Patients at the 2018 Annual Congress of the European Society of Gene and Cell Therapy...

Rocket Pharmaceuticals, Inc.  (RCKT) 
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: rocketpharma.com
PDF - RP-L102 Continues to Demonstrate Increasing and Durable Engraftment (Peripheral Vector Copy Number) In Fanconi Anemia Patients for Up to Thirty Months [Read more]